Copyright
©The Author(s) 2019.
World J Stem Cells. Oct 26, 2019; 11(10): 891-903
Published online Oct 26, 2019. doi: 10.4252/wjsc.v11.i10.891
Published online Oct 26, 2019. doi: 10.4252/wjsc.v11.i10.891
Study Population | Intervention | ||||||||||
Ref. | Country | Sample size | Age (yr) | Patient condition | Intervention and study groups | Application route | Type of stem cells | Source | Origin | Dose | |
Chen et al[45], 2013 | China | 60 | 1-35 | CP, GMFCS level 3 to 5 | Group 1: SC + rehabilitation Group 2: Rehabilitation only | Intrathecal | Mesenchymal stem cells in vitro transformed to neural stem cell- like cells | Bone marrow | Autologous | Fixed quantity of 1-2 × 107 cells, twice | |
Huang et al[46], 2018 | China | 56 | 3-12 | CP | Group 1: SC + rehabilitation Group 2: Placebo + rehabilitation | Intravenous | Mesenchymal stem cells | Cord blood | Allogeneic | Fixed quantity of 5 × 107 cells, 4 times | |
Kang et al[47], 2015 | South Korea | 36 | 0.5-20 | CP, GMFCS level 1 to 5 | Group 1: SC Group 2: Placebo No rehabilitation | Intravenous/intraarterial | Mononuclear cells | Cord blood | Allogeneic1 | 5.46 × 107 cells/kg, once | |
Liu et al[40], 2017 | China | 105 | 0.5-12.5 | Spastic CP, GMFCS level 2 to 5 | Group 1: MNC Group 2: MSC Group 3: rehabilitation | Intrathecal | Mesenchymal stromal cells and mononuclear cells | Bone marrow | Autologous | 106 cells/kg, 4 times | |
Luan et al[44], 2012 | China | 91 | < 0.5-3.5 | CP, GMFSC level 1 to 5 | Group 1: SC + rehabilitation Group 2: rehabilitation only | Intraventricular | Neural progenitor cells | Aborted healthy fetuses’ forebrains | Allogeneic | Fixed quantity of 8-10 × 106 cells, once | |
Min et al[39], 2013 | South Korea | 105 | 0.8-10 | CP | Group 1: SC+ EPO + rehabilitation Group 2: placebo SC + EPO + rehabilitation Group 3: placebo SC+ placebo + rehabilitation | Intravenous | Mononuclear cells | Cord blood | Allogeneic1 | ≥ 3 × 107 cells/kg, once | |
Rah et al[42], 2017 | South Korea | 57 | 2-10 | Non-severe CP | Group 1: G-CSF at baseline, SC 1 mo later Group 2: G-CSF at baseline, placebo 1 mo later crossover at 7 mo | Intravenous | Mobilized mononuclear cells | Peripheral blood | Autologous | 5.97 × 108 cells/ kg, once | |
Sun et al[41], 2017 | USA | 63 | 1-6 | CP of any type, GMFCS Level 2 to 4 or 1 with hemiplegia | Group 1: SC + rehabilitation Group 2: Placebo + rehabilitation | Intravenous | Mononuclear cells | Cord blood | Autologous | 2 × 107 cells/kg, once |
- Citation: Eggenberger S, Boucard C, Schoeberlein A, Guzman R, Limacher A, Surbek D, Mueller M. Stem cell treatment and cerebral palsy: Systemic review and meta-analysis. World J Stem Cells 2019; 11(10): 891-903
- URL: https://www.wjgnet.com/1948-0210/full/v11/i10/891.htm
- DOI: https://dx.doi.org/10.4252/wjsc.v11.i10.891